Drupal.behaviors.print = function(context) {window.print();window.close();}>
Qiagen, Max Planck Developing qPCR-Based Test for Active TB Risk in Latently Infected Patients
January 12, 2012
Qiagen, Max Planck Developing qPCR-Based Test for Active TB Risk in Latently Infected Patients
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Qiagen Teams with Max Planck on TB MDx Test
January 9, 2012 / GenomeWeb Daily News
Qiagen Q4, 2012 Growth Driven Significantly by QiaSymphony Sales in MDx, Applied Markets
January 31, 2013 / PCR Insider
Dx Focus: Clarient to Offer Qiagen Therascreen KRAS Test as Erbitux CDx
January 31, 2013 / PCR Insider
UPDATE: Qiagen Q2 Revenues Bounce 9 Percent; Plans to Buy Back $100M in Shares
July 25, 2012 / GenomeWeb Daily News
Securing FDA Clearance for Rotor-Gene Instrument and Flu Assay, Qiagen Looks to Expand IVD Test Menu
April 19, 2012 / PCR Insider